An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and thymosin beta-4. The panel turned down emideltide. Shares of HIMS climbed overnight following the committee's endorsement of four peptides. Bachem shares held steady after the vote. A recent study indicated peptides may aid treatment of antibiotic-resistant bacteria. Meanwhile, Kennedy called for broader availability to controversial peptides, calling for loosened oversight. The vote reflects a broader shift in how policymakers view compounded peptide therapies, which have drawn steady interest from users seeking alternatives to conventional drugs. Researchers say peptide treatments could change approaches to difficult infections, though concerns about quality persist. The committee's endorsement of four peptides paves the way for more expanded prescribing, even as critics warn of long-term evidence. Market watchers note that peptide-focused companies may see heightened investor attention following the panel's decision. The rejection of emideltide, meanwhile, underscores the FDA's cautious stance on particular peptide candidates.